Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 562 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Product E Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis

NCT02342691
View directory record Official record
Conditions
Gingival Inflammation
Interventions
BLXA4, Placebo oral rinse
Drug
Lead sponsor
The Forsyth Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 2, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection

NCT02378935
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
VOX, SOF/VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
31
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Sep 2, 2026, 7:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of E-Liquid Flavor on Respiratory Symptoms in People Using Electronic Nicotine Delivery Systems

NCT05423340
View directory record Official record
Conditions
Electronic Cigarette Use
Interventions
E-cigarette Flavor, Tobacco Free Nicotine Pouch
Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years to 55 Years
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 2, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults

NCT01458054
View directory record Official record
Conditions
Hepatitis C
Interventions
Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose), Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 2, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

NCT02279394
View directory record Official record
Conditions
Smoldering Myeloma, Smoldering Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
9
States / cities
Denver, Colorado • Hartford, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 2, 2026, 7:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

NCT01874054
View directory record Official record
Conditions
Hodgkin Disease
Interventions
brentuximab vedotin, bendamustine
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
13
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 2, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants

NCT06877702
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986460
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 2, 2026, 7:05 AM EDT
Completed Not applicable Interventional Results available

Effects of Cigarette and E-cigarette Flavors on Substitutability in the ETM

NCT06910202
View directory record Official record
Conditions
Cigarette Smoking Behavior
Interventions
Manipulation of nicotine/tobacco product price and availability
Behavioral
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
21 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 2, 2026, 7:05 AM EDT
Terminated Phase 2 Interventional Results available

PROCLAIM -- Misoprostol in the Prevention of Recurrent CDI Prevent Recurrence of Clostridium Difficile Infection With Misoprostol

NCT03617172
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Misoprostol 100Mcg Tab, Placebo
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
St Louis, Missouri • Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Sep 2, 2026, 7:05 AM EDT
Not yet recruiting Phase 3 Interventional

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

NCT07624513
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
Drug · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 2, 2026, 7:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

NCT00802074
View directory record Official record
Conditions
Healthy
Interventions
Raltegravir, Fosamprenavir, Ritonavir
Drug
Lead sponsor
Garden State Infectious Disease Associates, PA
Other
Eligibility
18 Years to 64 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Voorhees Township, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 28, 2016 · Synced Sep 2, 2026, 7:05 AM EDT
Terminated Phase 1 Interventional

Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

NCT02672917
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
MVT-5873, modified FOLFIRINOX (mFOLFIRINOX), gemcitabine + nab-paclitaxel
Drug
Lead sponsor
BioNTech Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
5
States / cities
Scottsdale, Arizona • Los Angeles, California • Sarasota, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 2, 2026, 7:05 AM EDT
Completed Phase 1 Interventional

Phase I Drug Trial for S/E of Marimastat in Disabling Malformations When no Other Options.

NCT00261391
View directory record Official record
Conditions
Vascular Anomalies
Interventions
Marimastat
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 8, 2008 · Synced Sep 2, 2026, 7:05 AM EDT
Recruiting Not applicable Interventional

Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection

NCT05219110
View directory record Official record
Conditions
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Interventions
Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
Other
Lead sponsor
University of Calgary
Other
Eligibility
9 Months to 21 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 2, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study

NCT00947856
View directory record Official record
Conditions
Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
Interventions
brentuximab vedotin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
6 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
16
States / cities
Birmingham, Alabama • Duarte, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Sep 2, 2026, 7:05 AM EDT
Completed Not applicable Interventional Results available

Changes in Biomarker of Exposure in Adults Who Smoke Cigarettes Switching From Cigarettes to Heated Tobacco Products

NCT06179290
View directory record Official record
Conditions
Tobacco Use
Interventions
Ploom HTP Menthol HTS; MX3 (681), Ploom HTP Tobacco HTS; R8 (120), Smoking Abstinence (menthol), Smoking Abstinence (non-menthol)
Other
Lead sponsor
Altria Client Services LLC
Industry
Eligibility
22 Years to 65 Years
Enrollment
921 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
Bentonville, Arkansas • Rogers, Arkansas • Overland Park, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 2, 2026, 7:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assisting Smokers to Switch to a JUUL E-Cigarette by Devaluing Combustible Cigarettes

NCT04188197
View directory record Official record
Conditions
Smoking Cessation, Harm Reduction, E-Cig Use, Cigarette Smoking, Tobacco Dependence, Tobacco Use Cessation
Interventions
JUUL
Other
Lead sponsor
Rose Research Center, LLC
Industry
Eligibility
21 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Charlotte, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2025 · Synced Sep 2, 2026, 7:05 AM EDT
Active, not recruiting Phase 1 Interventional

Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease

NCT03992469
View directory record Official record
Conditions
Crohn's Disease
Interventions
EBFAHF-2, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Sep 2, 2026, 7:05 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Impact of Increased Immunoglobulin E to Anti-herpes Simplex Virus -1 Innate Immune Responses in Atopic Dermatitis Patients With Eczema Herpeticum

NCT04060550
View directory record Official record
Conditions
Atopic Dermatitis With a History of Eczema Herpeticum, Atopic Dermatitis Without a History of Eczema Herpeticum, Health Controls Without Atopy
Interventions
Xolair
Biological
Lead sponsor
National Jewish Health
Other
Eligibility
16 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 2, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses

NCT00360737
View directory record Official record
Conditions
Healthy
Interventions
Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 2, 2026, 7:05 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)

NCT04009681
View directory record Official record
Conditions
Metastasis
Interventions
THOR-707, Checkpoint inhibitor, anti-EGFR antibody
Drug
Lead sponsor
Synthorx, Inc, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Scottsdale, Arizona • Denver, Colorado • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 2, 2026, 7:05 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088

NCT06579300
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-1088, Placebo for ABBV-1088, Itraconazole (ITZ)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Anaheim, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 2, 2026, 7:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

JUUL vs. Mod E-cigarette Study

NCT04237272
View directory record Official record
Conditions
Smoking, Tobacco Use
Interventions
Pod System E-cig, Customizable Tank E-cig, Control
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Sep 2, 2026, 7:05 AM EDT
Active, not recruiting Phase 1 Interventional

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

NCT02546661
View directory record Official record
Conditions
Muscle Invasive Bladder Cancer
Interventions
AZD4547, MEDI4736, Olaparib, AZD1775, Vistusertib, AZD9150, Selumetinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
8
States / cities
Los Angeles, California • New Haven, Connecticut • Fort Myers, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Sep 2, 2026, 7:05 AM EDT